Edition:
India

Erytech Pharma SA (ERYP.OQ)

ERYP.OQ on NASDAQ Stock Exchange Global Select Market

7.14USD
11 Aug 2020
Change (% chg)

$0.00 (+0.00%)
Prev Close
$7.14
Open
$7.69
Day's High
$13.95
Day's Low
$7.14
Volume
54,626
Avg. Vol
2,237
52-wk High
$13.95
52-wk Low
$3.50

Latest Key Developments (Source: Significant Developments)

Erytech Announces EUR 3 Million Convertible Bond Issue
Thursday, 25 Jun 2020 

June 25 (Reuters) - Erytech Pharma SA ::ERYTECH EXTENDS ITS CASH HORIZON BY IMPLEMENTING A CONVERTIBLE BOND FINANCING.NOTES COME WITH SHARE WARRANTS REPRESENTING 10% OF NOMINAL AMOUNT OF ISSUED NOTES.ANNOUNCED TODAY THE SIGNATURE OF AN AGREEMENT ALLOWING THE ISSUANCE FOR THE BENEFIT OF LUXEMBOURG-BASED EUROPEAN HIGH GROWTH OPPORTUNITIES SECURITIZATION FUND.AIMS AT IMPROVING COMPANY'S FINANCIAL STRENGTH AND EXTENDING ITS CASH HORIZON FOR NEXT KEY DEVELOPMENT MILESTONES.EXERCISE PRICE WILL REFLECT 20% PREMIUM OVER LOWEST VOLUME-WEIGHTED AVERAGE DAILY PRICE OF SHARE OVER REFERENCE PERIOD PRECEDING ISSUE OF FIRST TRANCHE.FINANCING FACILITY COMPRISES ZERO-COUPON NOTES AND LIMITED DISCOUNT ON CONVERSION, AS WELL AS MODERATE WARRANT COVERAGE WITH CLEAR INTEREST ALIGNMENT BETWEEN ERYTECH AND ALPHA BLUE OCEAN.NOTE WARRANTS MAY BE EXERCISED IN TRANCHES OVER A PERIOD OF 24 MONTHS FROM JUNE 25, 2020, I.E. UNTIL JUNE 25, 2022.NOTES, WITH NOMINAL VALUE OF EUR 50,000 EACH, WILL BE ISSUED UPON EXERCISE OF NOTE WARRANTS, IN ONE OR MORE TRANCHES, OF 60 NOTES CORRESPONDING TO TOTAL NOMINAL VALUE OF EUR 3 MILLION.ISSUANCE OF FIRST TRANCHE OF OCABSA TO BENEFIT OF INVESTOR IS EXPECTED TO TAKE PLACE IN JULY 2020.  Full Article

Erytech To Be Part Of EU-backed EVIDENCE Consortium
Wednesday, 6 May 2020 

May 6 (Reuters) - ERYTECH PHARMA SA ::ANNOUNCED ON TUESDAY IT WILL BE PART OF EVIDENCE, A PUBLIC-PRIVATE CONSORTIUM SUPPORTED BY EU.THE EVIDENCE CONSORTIUM WILL EXPLORE HOW RED BLOOD CELLS ARE INFLUENCED BY THEIR EXTRA-CELLULAR ENVIRONMENT.EU HAS PROVIDED 4 MILLION EUROS OF FUNDING FOR EVIDENCE PROJECT AS PART OF MARIE SKLODOWSKA-CURIE ACTIONS PROGRAM.  Full Article

Erytech Granted U.S. FDA Fast Track Designation For Eryaspase In Second-Line Pancreatic Cancer
Wednesday, 29 Apr 2020 

April 28 (Reuters) - Erytech Pharma SA ::ERYTECH GRANTED U.S. FDA FAST TRACK DESIGNATION FOR ERYASPASE IN SECOND-LINE PANCREATIC CANCER.  Full Article

Erytech Provides Update On The Trybeca-1 Phase 3 Clinical Trial Of Eryaspase In Second Line Pancreatic Cancer
Wednesday, 29 Apr 2020 

April 28 (Reuters) - Erytech Pharma SA ::ERYTECH PROVIDES UPDATE ON THE TRYBECA-1 PHASE 3 CLINICAL TRIAL OF ERYASPASE IN SECOND LINE PANCREATIC CANCER.ERYTECH PROVIDES UPDATE ON THE TRYBECA-1 PHASE 3 CLINICAL TRIAL OF ERYASPASE IN SECOND LINE PANCREATIC CANCER.ERYTECH PHARMA SA - TRIAL TO CONTINUE AS PLANNED AFTER THIRD SAFETY REVIEW BY INDEPENDENT DATA MONITORING COMMITTEE.ERYTECH PHARMA SA - INTERIM SUPERIORITY ANALYSIS EXPECTED AROUND YEAR-END; FINAL ANALYSIS IN SECOND HALF OF 2021.ERYTECH PHARMA SA - NO SAFETY ISSUES WERE IDENTIFIED AND IDMC RECOMMENDED TO CONTINUE TRIAL AS PLANNED.ERYTECH PHARMA SA - TO DATE, MORE THAN 75% OF APPROXIMATELY 500 PATIENTS TO BE ENROLLED IN TRIAL HAVE BEEN RANDOMIZED.  Full Article

Erytech Updates On Changes To Board Of Directors
Monday, 16 Mar 2020 

March 16 (Reuters) - ERYTECH PHARMA SA ::ERYTECH ANNOUNCES THE APPOINTMENT OF DR. MELANIE ROLLI TO ITS BOARD OF DIRECTORS.DR. ROLLI'S APPOINTMENT FOLLOWS RESIGNATION OF ALLENE DIAZ, WHO RESIGNED FROM BOARD EFFECTIVE SEPTEMBER 30, 2019.  Full Article

Erytech Announces Poster Presentation For TRYbeCA1
Friday, 24 Jan 2020 

Jan 24 (Reuters) - ERYTECH PHARMA SA ::ERYTECH ANNOUNCES A POSTER PRESENTATION FOR TRYBECA1 AT ASCO 2020.TRYBECA1 IS PLANNED TO ENROLL APPROXIMATELY 500 PATIENTS IN APPROXIMATELY 100 CLINICAL SITES IN EUROPE AND U.S..TO DATE, MORE THAN 50% OF PATIENTS FOR TRYBECA1 HAVE BEEN ENROLLED.PRIMARY ENDPOINT OF TRYBECA1 IS OVERALL SURVIVAL WITH AN INTERIM EFFICACY ANALYSIS PLANNED FOR WHEN APPROXIMATELY TWO-THIRDS OF EVENTS HAVE OCCURRED.CLINICAL TRIAL AUTHORIZATIONS HAVE BEEN OBTAINED FOR TRYBECA1 IN ELEVEN EUROPEAN COUNTRIES.TRIAL ACTIVELY ENROLLING PATIENTS IN MORE THAN 50 CLINICAL SITES IN EUROPE.WE EXPECT THAT AN INTERIM SUPERIORITY ANALYSIS OF TRYBECA1 WILL TAKE PLACE IN Q3 OF 2020, AS PLANNED-CHIEF MEDICAL OFFICER.  Full Article

Erytech 9-Month Net Loss Widens To EUR 43.3 Mln
Friday, 8 Nov 2019 

Nov 8 (Reuters) - Erytech Pharma SA ::ERYTECH PROVIDES BUSINESS UPDATE AND REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2019.9-MONTH OPERATING LOSS EUR 46.8 MLN VS LOSS OF EUR 33.6 MLN YR AGO.9-MONTH NET LOSS EUR 43.3 MLN VS LOSS OF EUR 29.6 MLN YR AGO.END-SEPT CASH POSITION EUR 81.9 MLN, vs EUR 134.4 MILLION ON DECEMBER 31, 2018.LEAD PROGRAM TRYBECA1, THE PHASE 3 TRIAL IN PANCREATIC CANCER, PROGRESSING ON PLAN.Q4 2019: SEES FIRST U.S. PATIENTS RANDOMIZED IN TRYBECA1 PHASE 3 CLINICAL TRIAL .H1 2020: SEES LAUNCH OF INVESTIGATOR SPONSORED PHASE 1 TRIAL IN FIRST-LINE METASTATIC PANCREATIC CANCER.H1 2020: SEES INTERIM RESULTS OF INVESTIGATOR SPONSORED PHASE 2 TRIAL IN SECOND-LINE ACUTE LYMPHOBLASTIC LEUKEMIA .Q3 2020: SEES INTERIM (SUPERIORITY) ANALYSIS IN TRYBECA1.  Full Article

Erytech Pharma H1 Net Loss Widens To 29.3 Million Euros
Wednesday, 18 Sep 2019 

Sept 18 (Reuters) - ERYTECH PHARMA : :REPORTED ON TUESDAY H1 NET LOSS EUR 29.3 MLN VS LOSS EUR 19.0 MLN YEAR AGO.H1 TOTAL OPERATING LOSS EUR 30.2 MLN VS LOSS EUR 21.9 MLN YEAR AGO.DR. JEAN PAUL KRESS APPOINTED AS CHAIRMAN.TRYBECA1, PHASE 3 TRIAL FOR ERYASPASE IN SECOND LINE PANCREATIC CANCER, PROGRESSING ON PLAN.CASH POSITION OF EUR 94.5 MILLION AT THE END OF JUNE.  Full Article

Erytech Pharma SA Files For Stock Shelf Of Upto $100 Mln
Wednesday, 17 Jul 2019 

July 16 (Reuters) - Erytech Pharma SA ::ERYTECH PHARMA SA FILES FOR STOCK SHELF OF UPTO $100 MILLION - SEC FILING.  Full Article

Erytech Announces Immune Modulation Strategic Collaboration With SQZ Biotechnologies
Tuesday, 25 Jun 2019 

June 25 (Reuters) - ERYTECH PHARMA SA ::ERYTECH ANNOUNCED ON MONDAY IT HAS ENTERED INTO AN AGREEMENT WITH SQZ BIOTECHNOLOGIES TO ADVANCE NOVEL RBC-BASED THERAPEUTICS FOR IMMUNE MODULATION.ERYTECH HAS GRANTED TO SQZ AN EXCLUSIVE WORLDWIDE LICENSE TO DEVELOP ANTIGEN-SPECIFIC IMMUNE MODULATING THERAPIES EMPLOYING RBC-BASED APPROACHES.ERYTECH IS ELIGIBLE TO RECEIVE UP TO $57 MLN IN COMBINED UPFRONT AND POTENTIAL DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS FOR FIRST PRODUCT SUCCESSFULLY DEVELOPED BY SQZ UNDER THIS AGREEMENT.ERYTECH ALSO ELIGIBLE TO RECEIVE SALES ROYALTIES, AND UP TO $50 MLN IN COMMERCIAL MILESTONE PAYMENTS RELATED TO EACH ADDITIONAL APPROVED PRODUCT OR APPROVED INDICATION.  Full Article

BRIEF-Erytech Announces EUR 3 Million Convertible Bond Issue

* ERYTECH EXTENDS ITS CASH HORIZON BY IMPLEMENTING A CONVERTIBLE BOND FINANCING